Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 plus radiotherapy for newly diagnosed diffuse intrinsic pontine glioma
ChiCTR2300074598Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dimethylaminomicheliolide in diffuse intrinsic pontine glioma (DIPG), sponsored by Beijing Tiantan Hospital. Primary endpoints: Objective response rate assessed by independent review committee (exploratory period), Adverse events during and after radiotherapy (exploratory period) and 2 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on ChiCTR2300074598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074598.